- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06481813
새로 진단된 폐암 환자를 포함하여 흉부 종양학의 전향적 종단적 생물 수집 (BREATHE)
BREATHE 코호트: 새로 진단된 폐암 환자를 포함하여 흉부 종양학의 전향적 종단적 생물 수집
In clinical trials, patients are selected according to strict eligibility criteria (inclusion and exclusion criteria). These criteria aim to ensure homogeneity within the trial population, but may omit patients with specific characteristics, comorbidities or co-medications. Indeed, patients of advanced age, with comorbidities or brain metastases, who are frequently encountered in clinical practice, are often excluded from clinical trials. Real-life data in oncology play a vital role in assessing the efficacy of therapies and therapeutic strategies, complementing data from controlled clinical trials. They make it possible to analyze a larger population and take into account multiple variables such as patient history, co-medications and comorbidities, but also to analyze efficacy and toxicity data in populations not represented in clinical trials. The establishment of a prospective cohort including various stages and histologies will make it possible to set up a platform of available data, including a maximum of data linked to the patient, his tumor and his treatments, collected longitudinally until the patient's death (or the end of the study).
In parallel with this cohort, the project aims to set up a longitudinal plasmatheque (from diagnosis to death, or at the end of the study), as well as a tumorotheque (samples systematically stored as part of care by the CHU tumorotheque, and for which patient consent allows their use in research depending on the material available) for patients with available tumor samples. This will enable the construction of ancillary projects to validate research hypotheses, for example concerning the identification of mechanisms of resistance to therapies.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Elvire PONS-TOSTIVINT, MD PhD
- 전화번호: 02.40.16.59.30
- 이메일: elvire.pons@chu-nantes.fr
연구 장소
-
-
-
Angers, 프랑스
- 아직 모집하지 않음
- CHU d'Angers
-
연락하다:
- Grégoire JUSTEAU, MD, PhD
- 전화번호: +33 2 41 35 36 37
- 이메일: gregoire.justeau@chu-angers.fr
-
수석 연구원:
- Grégoire JUSTEAU
-
Nantes, 프랑스
- 모병
- CHU Nantes
-
연락하다:
- Elvire PONS-TOSTIVINT, MD, PhD
- 전화번호: 02 40 16 59 30
- 이메일: elvire.pons@chu-nantes.fr
-
Rennes, 프랑스
- 아직 모집하지 않음
- CHU Rennes
-
수석 연구원:
- Charles RICORDEL
-
연락하다:
- Charles RICORDEL, MD, PhD
- 전화번호: +33 2 99 28 37 38
- 이메일: Charles.RICORDEL@chu-rennes.fr
-
Tours, 프랑스
- 아직 모집하지 않음
- CHU Tours
-
연락하다:
- Marion FERREIRA, MD, PhD
- 전화번호: +33 2.47.47.37.87
- 이메일: marion.ferreira@chu-tours.fr
-
수석 연구원:
- Marion FERREIRA
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Patients :
- Adult
- Patient newly diagnosed with NSCLC or CPC
- Cared for at Nantes University Hospital
- Affiliated or beneficiaries of a social security scheme or similar
- Treated with a systemic therapy including chemotherapy and/or immunotherapy and/or targeted therapy and/or therapy as part of a clinical trial after agreement from the sponsors of the studies concerned (only in the absence of blinding).
- Having agreed to participate in this study by signing the biocollection consent.
Healthy subjects :
- Adult
- Affiliated or beneficiaries of a social security or similar scheme
- Who have agreed to participate in this study by signing the Biocollection consent form.
- No known infectious pathology
- No known history of cancer
- No known history of chronic autoimmune disease
- No background immuno-suppressive treatment
Ancillary Study :
-Metastatic NSCLC with a KRAS G12C mutation, receiving treatment with Sotorasib, Adagrasib, or another KRAS G12C inhibitor, either as monotherapy or in combination.
Exclusion Criteria:
Patients :
- Previous anticancer treatment for Lung cancer
- Patients who have not consented to participate in the BREATHE collection
- History of cancer (excluding thoracic cancer) with evidence of disease for less than 2 years
- Inclusion in a therapeutic trial with blinded treatment
- Patients under guardianship
- Patients with AME.
- Pregnant or breast-feeding women
Healthy subjects :
- Person under guardianship
- Person benefiting from AME (State medical aid)
- Pregnant or breast-feeding women
Ancillary Study :
- Pregnant or breast-feeding women
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
다른: Cohort A
Patients are prospectively enrolled the day before their surgery for lung cancer, following selection based on tumor size assessed by the latest CT scan. The lesion size must be ≥ 20 mm (to prioritize anatomopathological analyses performed as part of care). If patients receive adjuvant treatment, blood samples will be collected on the day of treatment initiation and during follow-up. Patients receiving neoadjuvant treatment will be enrolled at the time of their first consultation with the medical oncologist. Patients in this cohort must meet the following criteria: - Stage I / II / IIIA-B localized NSCLC (non-small-cell lung cancer) eligible for surgery and adjuvant or neoadjuvant therapy (15-20% of NSCLC) Intervention : patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes) |
Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes) |
|
다른: Cohort B
Patients are prospectively enrolled at the diagnosis of lung neoplasm, during the establishment of the therapeutic plan by the referring oncologist or pneumo-oncologist. Enrollment can also occur at the initiation of first-line treatment if it was not done at the time of the diagnostic consultation. Patients in this cohort must meet the following criteria: - metastatic NSCLC or SCLC (small-cell bronchial cancers), with drained or punctured pleural effusion and anatomopathological evidence of tumor cells Intervention, the following volumes of blood will be drawn at each visit :
|
Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes) Patients will be sampled from 1 x 8 mL PBMC Patients will be sampled from 1 x 8 mL of blood with Paxgene Tube |
|
다른: Cohort C
Cohort C patients are recruited in the same way as for cohort B. Patients in this cohort must meet the following criteria:
Intervention, the following volumes of blood will be drawn at each visit :
|
Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes) Patients will be sampled from 1 x 8 mL PBMC Patients will be sampled from 1 x 8 mL of blood with Paxgene Tube |
|
다른: Cohort BMB
Patients are enrolled preoperatively, at the diagnosis of metastatic lung cancer at the cerebral level. The patient signs consent preoperatively (consent provided by the neurosurgeon). Subsequently, they are prospectively followed as part of their management in medical oncology, postoperatively. Patients in this cohort must meet the following criteria: - Patient operated on for brain metastasis as part of care, and diagnosed with lung cancer. Intervention, the following volumes of blood will be drawn at each visit :
|
Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes) Patients will be sampled from 1 x 8 mL PBMC Patients will be sampled from 1 x 8 mL of blood with Paxgene Tube |
|
다른: Healthy Controls :
A population of healthy subjects will also be included. These healthy subjects will be either :
Intervention : Healthy subject will be sampled from 2 x 8 mL blood tubes (EDTA tubes) In addition to blood samples from healthy subjects, healthy tissue remnants from atypical lung resections performed as part of care for pneumothorax management will be used to analyze the study objectives. A maximum of 30 healthy subjects are expected in this population. |
Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes) |
|
다른: Ancillary study
Patients included in the other arms of the cohort may also participate in the ancillary study if they meet the following conditions : Being carriers of metastatic KRAS G12C mutated NSCLC with a treatment plan involving sotorasib, adagrasib, or another KRAS inhibitor, either alone or in combination with another treatment. A target of 40 patients (among the 700 patients included in the cohort, excluding healthy subjects) is set for the ancillary study. |
Regarding the ancillary study, as part of the care, patients are biopsied at diagnosis and during relapse(s). For metastatic patients with multiple sites, one site (the most accessible) is chosen and biopsied in interventional radiology or pulmonology. The material used is: 17-18G biopsy needle / Sampling chamber volume of 0.01 cm³ to 0.02 cm³. For a standard biopsy as part of the care, 3 samples are taken (total volume of 0.03 cm³ to 0.06 cm³). Inclusion in the ancillary study would add one sample using the same biopsy path, resulting in an additional volume of 0.01 cm³ to 0.02 cm³. In the case of a complex biopsy, no additional sampling related to the research will be performed. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall survival
기간: up to 5 years
|
Overall survival will be defined as the time elapsed between the date of the initial diagnosis of lung cancer and the date of death, regardless of the cause. Patients still alive at the end of the follow-up period will complete their participation in the cohort. |
up to 5 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Describe the care pathway for patients with lung cancer. Assess the time intervals between different steps in the initial management of lung cancer.
기간: up to 5 years
|
The care pathway will be described through the collection of dates (surgery, radiotherapy, presentation at multidisciplinary consultation meetings, etc.) and types of medical consultations. |
up to 5 years
|
|
Evaluate the return to work for patients of working age who have been treated for lung cancer.
기간: up to 5 years
|
Proportion of patients who returned to work after treatment, measurement of the average time taken, and factors associated with the return to work. |
up to 5 years
|
|
Identify specific biomarkers of lung cancer cells (primary tumors or metastatic tissues) in comparison to healthy lung tissues.
기간: up to 5 years
|
Quantitative comparison and characterization of biomarkers (extracellular vesicles and miRNA signatures) between tumor tissues and non-cancerous tissues. |
up to 5 years
|
|
Evaluate the prognostic and predictive value of circulating biomarkers at diagnosis and during systemic treatments.
기간: up to 5 years
|
Association between levels of circulating biomarkers and overall survival as well as treatment response. |
up to 5 years
|
기타 결과 측정
결과 측정 |
기간 |
|---|---|
|
종양 및 혈장 샘플의 종적 분석을 통한 KRAS G12C 억제제에 대한 내성 발생 메커니즘 예측.
기간: 최대 5년
|
최대 5년
|
|
종양 및 혈장 샘플의 종적 분석을 통해 KRAS G12C 억제제에 대한 내성 발달 메커니즘 규명
기간: 최대 5년
|
최대 5년
|
|
전사적 변화가 sotorasib 또는 adagrasib 하에서 전이성 KRAS G12C 돌연변이 비소세포폐암 환자의 무진행 생존율을 예측할 수 있는지 여부를 결정합니다.
기간: 최대 5년
|
최대 5년
|
|
치료 중 발생하는 특정 분자적 변화의 검출에 대한 예후적 가치 평가
기간: 최대 5년
|
최대 5년
|
|
진행 중인 환자의 종양 및 혈장 샘플에서 새로운 분자 변이를 검출할 수 있는지 확인.
기간: 최대 5년
|
최대 5년
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- RC21_0541
- 2024-A00509-38 (기타 식별자: ANSM (IDRCB))
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .